Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 8, 2004, Pages 2966-2972

  Karunajeewa, Harin A ^a   Ilett, Kenneth F ^a,b   Dufall, Kitiya ^g   Kemiki, Adedayo ^d   Bockarie, Moses ^e   Alpers, Michael P ^c   Barrett, P Hugh ^a   Vicini, Paolo ^f   Davis, Timothy M E ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Western Australian Centre for Pathology and Medical Research   (Australia)

^c CURTIN UNIVERSITY   (Australia)

^d Modilon General Hospital   (Papua New Guinea)

^e PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^f University of Washington   (United States)

^g Fremantle Hospital ^*

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; DIHYDROARTEMISININ;

AGE; ALPHA THALASSEMIA; ARTICLE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; GENDER; HUMAN; LIQUID CHROMATOGRAPHY; MALARIA; MALARIA FALCIPARUM; MALE; MASS SPECTROMETRY; PAPUA NEW GUINEA; PLASMODIUM VIVAX; PRIORITY JOURNAL; SIDE EFFECT; SUPPOSITORY;

AGING; ALPHA-THALASSEMIA; ANTIMALARIALS; ARTEMISININS; BODY WEIGHT; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GENOTYPE; HALF-LIFE; HUMANS; MALARIA; MALE; MODELS, STATISTICAL; PAPUA NEW GUINEA; POPULATION; SESQUITERPENES; SEX CHARACTERISTICS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SUPPOSITORIES; TISSUE DISTRIBUTION;

EID: 3342899925     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.8.2966-2972.2004     Document Type: Article

References (42)

1. Allen, S. J., A. O'Donnell, N. D. E. Alexander, M. P. Alpers, T. E. A. Peto, J. B. Clegg, and D. J. Weatherall. 1997. α+-Thalassemia protects children against disease caused by other infections as well as malaria. Proc. Natl. Acad. Sci. USA 94:14736-14741.
2. Angus, B. J., I. Thaiaporn, K. Chanthapadith, Y. Suputtamongkol, and N. J. White. 2002. Oral artesunate dose-response relationship in acute falciparum malaria. Antimicrob. Agents Chemother. 46:778-782.
3. Ashton, M., D. S. Nguyen, V. H. Nguyen, T. Gordi, N. H. Trinh, X. H. Dinh, T. N. Nguyen, and D. C. Le. 1998. Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria. Clin. Pharmacol. Ther. 63:482-493.
4. Awad, M. I., A. M. Y. Alkadru, R. H. Behrens, O. Z. Baraka, and I. B. Eltayeb. 2003. Descriptive study on the efficacy and safety of artesunate suppository in combination with other antimalarials in the treatment of severe malaria in Sudan. Am. J. Trop. Med. Hyg. 63:153-158.
5. Batty, K. T., A. T. Le, K. F. Ilett, P. T. Nguyen, S. M. Powell, C. H. Nguyen, X. M. Truong, V. C. Vuong, V. T. Huynh, Q. B. Tran, V. M. Nguyen, and T. M. Davis. 1998. A pharmacokinetic and pharmacodynamic study of artesunate for vivax malaria. Am. J. Trop. Med. Hyg. 59:823-827.
6. Batty, K. T., L. T. Thu, T. M. Davis, K. F. Ilett, T. X. Mai, N. C. Hung, N. P. Tien, S. M. Powell, H. V. Thien, T. Q. Binh, and N. V. Kim. 1998. A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. Br. J. Clin. Pharmacol. 45:123-129.
7. Beal, S. L., and L. B. Sheiner. 1992. NONMEM user guide. NONMEM Project Group, University of California San Francisco, San Francisco.
8. Brewer, T. G., J. O. Peggins, S. J. Grate, J. M. Petras, B. S. Levine, P. J. Weina, H. Searengen, M. H. Heffer, and B. G. Schuster. 1994. Neurotoxicity in animals due to arteether and artemether. Trans. R. Soc. Trop. Med. Hyg. 88:33-36.
9. Cattani, J. A., J. L. Tulloch, H. Vrbova, D. Jolley, F. D. Gibson, J. S. Moir, P. F. Heywood, M. P. Alpers, A. Stevenson, and R. Clancy. 1986. The epidemiology of malaria in a population surrounding Madang, Papua New Guinea. Am. J. Trop. Med. Hyg. 35:3-15.
10. Charoenteeraboon, J., S. Kamchonwongpaisan, P. Wilairat, P. Vattanaviboon, and Y. Yuthavong. 2000. Inactivation of artemisinin by thalassemic erythrocytes. Biochem. Pharmacol. 59:1337-1344.
11. Chong, S. S., C. D. Boehm, D. R. Higgs, and G. R. Cutting. 2000. Single-tube multiplex-PCR screen for common deletional determinants of alpha-thalassemia. Blood 95:360-362.
12. Davis, T. M., H. L. Phuong, K. F. Ilett, N. C. Hung, K. T. Batty, V. D. Phuong, S. M. Powell, H. V. Thien, and T. Q. Binh. 2001. Pharmacokinetics and pharmacodynamics of intravenous artesunate in severe falciparum malaria. Antimicrob. Agents Chemother. 45:181-186.
13. Halpaap, B., M. Ndjave, M. Paris, A. Benakis, and P. G. Kremsner. 1998. Plasma levels of artesunate and dihydroartemisinin in children with Plasmodium falciparum malaria in Gabon after administration of 50-milligram artesunate suppositories. Am. J. Trop. Med. Hyg. 58:365-368.
14. Hassan Alin, M., M. Ashton, C. M. Kihamia, G. J. Mtey, and A. Bjorkman. 1996. Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients. Trans. R. Soc. Trop. Med. Hyg. 90:61-65.
15. Heinzel, G., and P. Tanswell. 1993. Compartmental analysis methods manual, p. 5-140. In G. Heinzel, R. Woloszcak, and P. Thomann (ed.), Topfit 2.0 pharmacokinetic and pharmacodynamic data analysis system for the PC. Gustav Fischer, Stuttgart, Germany.
16. Hien, T. T., G. D. H. Turner, N. T. H. Mai, N. H. Phu, D. Bethell, W. F. Blakemore, J. B. Cavanagh, A. Dayan, I. Medana, R. O. Weller, N. P. J. Day, and N. J. White. 2003. Neuropathological assessment of artemether-treated severe malaria. Lancet 362:395-396.
17. Hien, T. T., and N. J. White. 1993. Qinghaosu. Lancet 341:603-607.
18. Ilett, K. F., K. T. Batty, S. M. Powell, T. Q. Binh, T. A. Thu le, H. L. Phuong, N. C. Hung, and T. M. Davis. 2002. The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria. Br. J. Clin. Pharmacol. 53:23-30.
19. Ilett, K. F., B. T. Ethell, J. L. Maggs, T. M. Davis, K. T. Batty, B. Burchell, T. Q. Binh, T. A. Thu le, N. C. Hung, M. Pirmohamed, and B. K. Park. 2002. Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab. Dispos. 30:1005-1012.
20. Ittarat, W., S. Looareesuwan, P. Pootrakul, P. Sumpunsirikul, P. Vattanavibool, and S. R. Meshnick. 1998. Effects of alpha-thalassemia on pharmacokinetics of the antimalarial agent artesunate. Antimicrob. Agents Chemother. 42:2332-2335.
21. Johann-Liang, R., and R. Albrecht. 2003. Safety evaluations of drugs containing artemisinin derivatives for the treatment of malaria. Clin. Infect. Dis. 36:1626-1627.
22. Kamchonwongpaisan, S., G. Chandrangam, M. A. Avery, and Y. Yuthavong. 1994. Resistance to artemisinin of malaria parasites (Plasmodium falciparum) infecting alpha-thalassemic erythrocytes in vitro. Competition in drug accumulation with uninfected erythrocytes. J. Clin. Investig. 93:467-473.
23. Karunajeewa, H. A., A. Kemiki, M. P. Alpers, K. Lorry, K. T. Batty, K. F. Ilett, and T. M. Davis. 2003. Safety and therapeutic efficacy of artesunate suppositories for treatment of malaria in children in Papua New Guinea. Pediatr. Infect. Dis. J. 22:251-256.
24. Klaanh, N. X., P. J. De Vries, L. D. Ha, C. J. van Boxtel, R. Koopmans, and P. A. Kager. 1999. Declining concentrations of dihydroartemisinin in plasma during 5-day oral treatment with artesunate for falciparum malaria. Antimicrob. Agents Chemother. 43:690-692.
25. Krishna, S., T. Planche, T. Agbenyega, C. Woodrow, D. Agranoff, G. Bedu-Addo, A. K. Owusu-Ofori, J. A. Appiah, S. Ramanathan, S. M. Mansor, and V. Navaratnam. 2001. Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria. Antimicrob. Agents Chemother. 45:509-516.
26. Lee, I. S., and C. D. Hufford. 1990. Metabolism of antimalarial sesquiterpene lactones. Pharmacol. Ther. 48:345-355.
27. Li, Q. G., S. R. Mog, Y. Z. Si, D. E. Kyle, M. Gettayacamin, and M. K. Milhous. 2002. Neurotoxicity and efficacy of arteether related to its exposure times and exposure levels in rodents. Am. J. Trop. Med. Hyg. 66:516-525.
28. Looareesuwan, S., C. Viravan, S. Vanijanonta, P. Wilairatana, P. Pitisuttithum, and M. Andrial. 1996. Comparative clinical trial of artesunate followed by mefloquine in the treatment of acute uncomplicated falciparum malaria: two and three-day regimens. Am. J. Trop. Med. Hyg. 54:210-213.
29. Looareesuwan, S., P. Wilairatana, S. Vanijanonta, C. Viravan, and M. Andrial. 1995. Efficacy and tolerability of a sequential, artesunate suppository plus mefloquine, treatment of severe falciparum malaria. Ann. Trop. Med. Parasitol. 89:469-475.
30. McIntosh, H. M., and P. Olliaro. 2000. Artemisinin derivatives for treating complicated malaria (Cochrane review). In The Cochrane library, issue 2. John Wiley & Sons, Ltd., Chichester, United Kingdom.
31. McIntosh, H. M. and P. Olliaro. 2000. Artemisinin derivatives for treating uncomplicated malaria (Cochrane review). In The Cochrane library, issue 2. John Wiley & Sons, Ltd., Chichester, United Kingdom.
32. Newton, P., Y. Suputtamongkol, P. Teja-Isavadharm, S. Pukrittayakamee, V. Navaratnam, I. Bates, and N. White. 2000. Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria. Antimicrob. Agents Chemother. 44:972-977.
33. Sabchareon, A., P. Attanath, P. Chanthavanich, P. Phanuaksook, V. Prarinyanupharb, Y. Poonpanich, D. Mookmanee, P. Teja-Isavadharm, D. G. Heppner, T. G. Brewer, and T. Chongsuphajaisiddhi. 1998. Comparative clinical trial of artesunate suppositories and oral artesunate in combination with mefloquine in the treatment of children with acute falciparum malaria. Am. J. Trop. Med. Hyg. 58:11-16.
34. Senok, A. C., E. A. Nelson, K. Li, and S. J. Oppenheimer, 1997. Thalassaemia trait, red blood cell age and oxidant stress: effects on Plasmodium falciparum growth and sensitivity to artemisinin. Trans. R. Soc. Trop. Med. Hyg. 91:585-589.
35. Silamut, K., P. N. Newton, P. Teja-Isavadharm, Y. Suputtamongkol, D. Siriyanonda, M. Rasameesoraj, S. Pukrittayakamee, and N. J. White. 2003. Artemether bioavailability after oral or intramuscular administration in uncomplicated falciparum malaria. Antimicrob. Agents Chemother. 47:3795-3798.
36. Svensson, U. S., M. Maki-Jouppila, K. J. Hoffman, and M. Ashton. 2003. Characterisation of the human liver in vitro metabolic pattern of artemisinin and auto-induction in the rat by use of nonlinear mixed effects modelling. Biopharm. Drug Dispos. 24:71-85.
37. Vattanaviboon, P., N. Sirianaratkul, J. Ketpriune, P. Wilairat, and Y. Yuthavong. 2002. Membrane heme as a host factor in reducing effectiveness of dihydroartemisinin. Biochem. Pharmacol. 64:91-98.
38. Vattanaviboon, P., P. Wilairat, and Y. Yuthavong. 1998. Binding of dihydro-artemisinin to hemoglobin H: role in drug accumulation and host-induced antimalarial ineffectiveness of alpha-thalassemic erythrocytes. Mol. Pharmacol. 53:492-496.
39. World Health Organization. 2000. Severe falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 94(Suppl. 1):1-90.
40. World Health Organization. Special Programme for Research and Training in Tropical Diseases. 15th Programme Report. Progress 1999-2000. Report TDR/GEN/01.5. World Health Organization, Geneva, Switzerland.
41. World Health Organization. 1998. The use of artemisinin and its derivatives as anti-malarial drugs. Report WHO/MAL 1086. World Health Organization, Geneva, Switzerland.
42. Zhang, S. Q., T. N. Hai, K. F. Ilett, D. X. Huong, T. M. Davis, and M. Ashton. 2001. Multiple dose study of interactions between artesunate and artemisinin in healthy volunteers. Br. J. Clin. Pharmacol. 52:377-385.